Bay Area Biotech Companies: Technology and Market Analysis

Mar 25, 2006, Sat, 2006, 2-5 PM at Los Altos Library Community Room

CBA is hosting a March seminar introducing the technology and core business of 6-8 Biotech companies in the Bay Area. We have invited scientific or business managers from Abgenix (Amgen), Amgen, Foothill College, Genomic Health, Iconix, Medarex, Nuvelo, and Roche Diagnostics to give us an analysis of their core technology and business. You are cordially invited to share their insights into the tremendous energy and promise of biotech!

Chu Chang Genomic Health

Grace Chen Abgenix (Amgen)

Gwo-Jen Day, PhD Iconix

Kelley Liu, PhD Foothill College

Yi Liu, PhD Nuvelo

Chin Pan, PhD Medarex Medarex

Wenyan David Shen, PhD Amgen Amgen's Protein Platform

Xiaoni Wu, PhD Roche Diagnostics

Chin Pan, PhD, Medarex

Ph.D. University of Massachusetts at Amherst Molecular and Cellular Biology 1994
Postdoctoral Fellow, Stanford University, Immunology, 1994-1998
Research Scientist, 1999-2002, Coulter Pharmaceutical/Corixa
Senior Scientist, 2002-present, Medarex Inc

Wenyan David Shen, PhD, Amgen

Wenyan David Shen, Ph.D., is an Associate Director and head of the Protein Science Department in Amgen San Francisco. He directs a group of Scientists with diversified functions. These include antibody drug development, protein expression, purification and characterization. His department supports therapeutic antibody and protein based drug developments for Cancer, Inflammation, Metabolic Diseases, and Neurobiology. He holds numerous antibody drug and technology patents in Amgen.

Prior to joining Amgen in July 1995, David was a Post-doctoral Fellow at the Whitehead Institute, MIT at the Cambridge, MA. His work involved protein engineering and protein-protein interaction.

David's educational background includes a Bachelor of Science from East China University of Technology in Shanghai, China in 1983. He later moved to Canada for a Ph.D. degree in Molecular Biology from University of Toronto in 1991.